Report Detail
Global Oncology Biosimilars Market by Manufacturers, Regions, Type and Application, Forecast to 2025
- RnM3847195 |
- 12 December, 2019 |
- Global |
- 107 Pages |
- XYZResearch |
- Medical Devices & Consumables
In this report, the study analysis was given on a worldwide scale, for instance, present and traditional Oncology Biosimilarsgrowth analysis, competitive analysis, and also the growth prospects of the central regions. The report gives an exhaustive investigation of this market at country & regional levels, and provides an analysis of the industry trends in each of the sub-segments, from sales, revenue and consumption. A quantitative and qualitative analysis of the main players in related regions is introduced, from the perspective of sales, revenue and price.
According to XYZResearch, the global Oncology Biosimilars market was valued at USD xxx million in 2019, and it is expected to reach a value of USD xxx million by 2026, at a CAGR of xx% over the forecast period 2021-2026. Correspondingly, the forecast analysis of Oncology Biosimilars industry comprises of Asia, North America, South America, Middle East and Africa, Europe, with the sales and revenue data in each of the sub-segments.
At the upcoming section, this report discusses industrial policy, economic environment, in addition to the fabrication processes and cost structures of the industry. And this report encompasses the fundamental dynamics of the market which include drivers, opportunities, and challenges faced by the industry. Additionally, this report showed a keen market study of the main consumers, raw material manufacturers and distributors, etc.
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (M USD), market share and growth rate of Oncology Biosimilars in these regions, from 2014 to 2026 (forecast), covering
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
South America (Brazil, Argentina, Columbia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Global Oncology Biosimilars market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
Celltrion Inc.
Pfizer Inc.
Biocon
BIOCAD
Apotex Inc.
Dr. Reddy's Laboratories Ltd.
Sandoz International GmbH
Intas Pharmaceuticals Ltd.
STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd.
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
G-CSF
Hematopoietic Agents
Monoclonal Antibodies
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Oncology Biosimilars for each application, including
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
If you have any special requirements, please let us know and we will offer you the report as you want.
Table of Contents
Global Oncology Biosimilars Market by Manufacturers, Regions, Type and Application, Forecast to 2026
1 Report Overview
- 1.1 Definition and Specification
- 1.2 Report Overview
- 1.2.1 Manufacturers Overview
- 1.2.2 Regions Overview
- 1.2.3 Type Overview
- 1.2.4 Application Overview
- 1.3 Industrial Chain
- 1.3.1 Oncology Biosimilars Overall Industrial Chain
- 1.3.2 Upstream
- 1.3.3 Downstream
- 1.4 Industry Situation
- 1.4.1 Industrial Policy
- 1.4.2 Product Preference
- 1.4.3 Economic/Political Environment
- 1.5 SWOT Analysis
2 Market Assessment by Type
- 2.1 G-CSF Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
- 2.2 Hematopoietic Agents Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
- 2.3 Monoclonal Antibodies Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
3 Asia Pacific Oncology Biosimilars Market Assessment by Type
- 3.1 Asia Pacific Market Performance (Sales, Revenue)
- 3.2 Key Players in Asia Pacific
4 North America Oncology Biosimilars Market Assessment by Type
- 4.1 North America Market Performance (Sales, Revenue)
- 4.2 Key Players in North America
5 Europe Oncology Biosimilars Market Assessment by Type
- 4.1 Europe Market Performance (Sales, Revenue)
- 4.2 Key Players in Europe
6 South America Oncology Biosimilars Market Assessment by Type
- 4.1 South America Market Performance (Sales, Revenue)
- 4.2 Key Players in South America
7 Middle Easr and Africa Oncology Biosimilars Market Assessment by Type
- 4.1 Middle Easr and Africa Market Performance (Sales, Revenue)
- 4.2 Key Players in Middle Easr and Africa
8 World Oncology Biosimilars Market Assessment by Type
- 8.1 Asia Pacific Oncology Biosimilars Market Assessment by Application (Consumption and Market Share)
- 8.2 North America Oncology Biosimilars Market Assessment by Application (Consumption and Market Share)
- 8.3 Europe Oncology Biosimilars Market Assessment by Application (Consumption and Market Share)
- 8.4 South America Oncology Biosimilars Market Assessment by Application (Consumption and Market Share)
- 8.5 Middle East and Africa Oncology Biosimilars Market Assessment by Application (Consumption and Market Share)
9 Company Profiles/Analysis
- 9.1 Celltrion Inc.
- 9.1.1 Celltrion Inc. Profiles
- 9.1.2 Celltrion Inc. Product Portfolio
- 9.1.3 Celltrion Inc. Oncology Biosimilars Business Performance
- 9.1.4 Celltrion Inc. Oncology Biosimilars Business Development and Market Status
- 9.2 Pfizer Inc.
- 9.2.1 Pfizer Inc. Profiles
- 9.2.2 Pfizer Inc. Product Portfolio
- 9.2.3 Pfizer Inc. Oncology Biosimilars Business Performance
- 9.2.4 Pfizer Inc. Oncology Biosimilars Business Development and Market Status
- 9.3 Biocon
- 9.3.1 Biocon Profiles
- 9.3.2 Biocon Product Portfolio
- 9.3.3 Biocon Oncology Biosimilars Business Performance
- 9.3.4 Biocon Oncology Biosimilars Business Development and Market Status
- 9.4 BIOCAD
- 9.4.1 BIOCAD Profiles
- 9.4.2 BIOCAD Product Portfolio
- 9.4.3 BIOCAD Oncology Biosimilars Business Performance
- 9.4.4 BIOCAD Oncology Biosimilars Business Development and Market Status
- 9.5 Apotex Inc.
- 9.5.1 Apotex Inc. Profiles
- 9.5.2 Apotex Inc. Product Portfolio
- 9.5.3 Apotex Inc. Oncology Biosimilars Business Performance
- 9.5.4 Apotex Inc. Oncology Biosimilars Business Development and Market Status
- 9.6 Dr. Reddy's Laboratories Ltd.
- 9.6.1 Dr. Reddy's Laboratories Ltd. Profiles
- 9.6.2 Dr. Reddy's Laboratories Ltd. Product Portfolio
- 9.6.3 Dr. Reddy's Laboratories Ltd. Oncology Biosimilars Business Performance
- 9.6.4 Dr. Reddy's Laboratories Ltd. Oncology Biosimilars Business Development and Market Status
- 9.7 Sandoz International GmbH
- 9.7.1 Sandoz International GmbH Profiles
- 9.7.2 Sandoz International GmbH Product Portfolio
- 9.7.3 Sandoz International GmbH Oncology Biosimilars Business Performance
- 9.7.4 Sandoz International GmbH Oncology Biosimilars Business Development and Market Status
- 9.8 Intas Pharmaceuticals Ltd.
- 9.8.1 Intas Pharmaceuticals Ltd. Profiles
- 9.8.2 Intas Pharmaceuticals Ltd. Product Portfolio
- 9.8.3 Intas Pharmaceuticals Ltd. Oncology Biosimilars Business Performance
- 9.8.4 Intas Pharmaceuticals Ltd. Oncology Biosimilars Business Development and Market Status
- 9.9 STADA Arzneimittel AG
- 9.9.1 STADA Arzneimittel AG Profiles
- 9.9.2 STADA Arzneimittel AG Product Portfolio
- 9.9.3 STADA Arzneimittel AG Oncology Biosimilars Business Performance
- 9.9.4 STADA Arzneimittel AG Oncology Biosimilars Business Development and Market Status
- 9.10 Teva Pharmaceutical Industries Ltd.
- 9.10.1 Teva Pharmaceutical Industries Ltd. Profiles
- 9.10.2 Teva Pharmaceutical Industries Ltd. Product Portfolio
- 9.10.3 Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Business Performance
- 9.10.4 Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Business Development and Market Status
10 World Oncology Biosimilars Market Assessment by Players
- 10.1 Global Oncology Biosimilars Sales (K Units) and Market Share by Players 2014-2020
- 10.2 Global Oncology Biosimilars Revenue (M USD) and Market Share by Players 2014-2020
- 10.3 Global Oncology Biosimilars Price (USD/Unit) of Players 2014-2020
- 10.4 Global Oncology Biosimilars Gross Margin of Players 2014-2020
- 10.5 Market Concentration
11 Regional Market Performance by Segment of Players
- 11.1 North America
- 11.1.1 North America Oncology Biosimilars Sales Assessment of Players 2014-2020
- 11.1.2 North America Oncology Biosimilars Revenue Assessment of Players 2014-2020
- 11.1.3 North America Oncology Biosimilars Price Assessment of Players 2014-2020
- 11.1.4 North America Oncology Biosimilars Gross Margin Assessment of Players 2014-2020
- 11.1.5 Market Concentration
- 11.2 Europe
- 11.2.1 Europe Oncology Biosimilars Sales Assessment of Players 2014-2020
- 11.2.2 Europe Oncology Biosimilars Revenue Assessment of Players of Manufacturers 2014-2020
- 11.2.3 Europe Oncology Biosimilars Price Assessment of Players 2014-2020
- 11.2.4 Europe Oncology Biosimilars Gross Margin Assessment of Players 2014-2020
- 11.2.5 Market Concentration
- 11.3 Asia-Pacific Market Performance for Manufacturers
- 11.3.1 Asia-Pacific Oncology Biosimilars Sales Assessment of Players 2014-2020
- 11.3.2 Asia-Pacific Oncology Biosimilars Revenue Assessment of Players 2014-2020
- 11.3.3 Asia-Pacific Oncology Biosimilars Price Assessment of Players 2014-2020
- 11.3.4 Asia-Pacific Oncology Biosimilars Gross Margin Assessment of Players 2014-2020
- 11.3.5 Market Concentration
- 11.4 South America Market Performance for Players
- 11.4.1 South America Oncology Biosimilars Sales Assessment of Players 2014-2020
- 11.4.2 South America Oncology Biosimilars Revenue Assessment of Players 2014-2020
- 11.4.3 South America Oncology Biosimilars Price Assessment of Players 2014-2020
- 11.4.4 South America Oncology Biosimilars Gross Margin Assessment of Players 2014-2020
- 11.4.5 Market Concentration
- 11.5 Middle East and Africa Market Performance for Players
- 11.5.1 Middle East and Africa Oncology Biosimilars Sales Assessment of Players 2014-2020
- 11.5.2 Middle East and Africa Oncology Biosimilars Revenue Assessment of Players 2014-2020
- 11.5.3 Middle East and Africa Oncology Biosimilars Price Assessment of Players 2014-2020
- 11.5.4 Middle East and Africa Oncology Biosimilars Gross Margin Assessment of Players 2014-2020
- 11.5.5 Market Concentration
12 Regional Market Performance by Segment of Countries
- 12.1 Asia Pacific
- 12.1.1 Asia Pacific Oncology Biosimilars Sales by Countries/Regions 2014-2020
- 12.1.2 Asia Pacific Oncology Biosimilars Revenue by Countries/Regions 2014-2020
- 12.1.3 Asia Pacific Oncology Biosimilars Average Price by Countries/Regions 2014-2020
- 12.2 North America
- 12.2.1 North America Oncology Biosimilars Sales by Countries/Regions 2014-2020
- 12.2.2 North America Oncology Biosimilars Revenue by Countries/Regions 2014-2020
- 12.2.3 North America Oncology Biosimilars Average Price by Countries/Regions 2014-2020
- 12.3 Europe
- 12.3.1 Europe Oncology Biosimilars Sales by Countries/Regions 2014-2020
- 12.3.2 Europe Oncology Biosimilars Revenue by Countries/Regions 2014-2020
- 12.3.3 Europe Oncology Biosimilars Average Price by Countries/Regions 2014-2020
- 12.4 South America
- 12.4.1 South America Oncology Biosimilars Sales by Countries/Regions 2014-2020
- 12.4.2 South America Oncology Biosimilars Revenue by Countries/Regions 2014-2020
- 12.4.3 South America Oncology Biosimilars Average Price by Countries/Regions 2014-2020
- 12.5 Middle East and Africa
- 12.5.1 Middle East and Africa Oncology Biosimilars Sales by Countries/Regions 2014-2020
- 12.5.2 Middle East and Africa Oncology Biosimilars Revenue by Countries/Regions 2014-2020
- 12.5.3 Middle East and Africa Oncology Biosimilars Average Price by Countries/Regions 2014-2020
13 Technology and Opportunity
- 13.1 Technology
- 13.2 Market Opportunity
14 World Oncology Biosimilars Sales & Revenue Forecast 2021-2026
- 14.1 World Oncology Biosimilars Sales and Revenue Forecast by Regions 2021-2026
- 14.1.1 World Oncology BiosimilarsSales and Market Share by Regions
- 14.1.2 World Oncology BiosimilarsRevenue and Market Share by Regions
15 Asia Oncology Biosimilars Market Forecast 2021-2026
- 15.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
- 15.1.1 G-CSF
- 15.1.2 Hematopoietic Agents
- 15.1.3 Monoclonal Antibodies
- 15.2 Consumption Forecast by Application, 2021-2026
16 North America Oncology Biosimilars Market Forecast 2021-2026
- 16.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
- 16.1.1 G-CSF
- 16.1.2 Hematopoietic Agents
- 16.1.3 Monoclonal Antibodies
- 16.2 Consumption Forecast by Application, 2021-2026
17 Europe Oncology Biosimilars Market Forecast 2021-2026
- 17.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
- 17.1.1 G-CSF
- 17.1.2 Hematopoietic Agents
- 17.1.3 Monoclonal Antibodies
- 17.2 Consumption Forecast by Application, 2021-2026
18 South America Oncology Biosimilars Market Forecast 2021-2026
- 18.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
- 18.1.1 G-CSF
- 18.1.2 Hematopoietic Agents
- 18.1.3 Monoclonal Antibodies
- 18.2 Consumption Forecast by Application, 2021-2026
19 Middle East and Africa Oncology Biosimilars Market Forecast 2021-2026
- 19.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
- 19.1.1 G-CSF
- 19.1.2 Hematopoietic Agents
- 19.1.3 Monoclonal Antibodies
- 19.2 Consumption Forecast by Application, 2021-2026
20 Price (USD/Unit) and Gross Profit Forecast
- 20.1 Global Oncology Biosimilars Price (USD/Unit) Trend 2021-2026
- 20.2 Global Oncology Biosimilars Gross Profit Trend 2021-2026
21 Conclusion
Summary:
Get latest Market Research Reports on Oncology Biosimilars . Industry analysis & Market Report on Oncology Biosimilars is a syndicated market report, published as Global Oncology Biosimilars Market by Manufacturers, Regions, Type and Application, Forecast to 2025. It is complete Research Study and Industry Analysis of Oncology Biosimilars market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
